Artist collective brings carbon-absorbing murals to Houston

WHEN FINE ART MEETS FRESH AIR

For 713 Day, UXD created carbon-absorbing mural "(HUE)STON HARMONY" in collaboration with Downtown Houston+ and local artist David Maldonado. Photo courtesy of Egidio Narvaez

Anthony Rose, the CEO of creative agency United By Design, is on a mission to brighten Houston’s urban spaces and improve the city’s air quality one carbon-absorbing mural at a time.

Rose originally founded United By Design, or UXD, in 2019 to connect muralists like himself and commercial businesses seeking to beautify their spaces and form brand identities. After creating vibrant murals for Lockhart Elementary School, the Houston Astros, and Smoothie King, Rose expanded UXD’s vision to include environmental sustainability in their artistic collaborations in 2022.

“This city’s vibrant art scene and growing focus on sustainability makes it an ideal location for our projects,” Rose says. “We’re not just creating eco-friendly murals, we’re reimagining how art can actively contribute to environmental solutions.”

In search of ecologically-conscious paints, Rose formed a partnership with Spain-based, natural paint company Graphenstone. Rose says he was drawn to the company’s eponymous Graphenstone coating because of its nontoxic ingredients and exclusively uses the product for UXD’s carbon-absorbing murals.

"Between Land and Sky" by artist David Maldonado was UXD's first carbon-absorbing painting. Photo courtesy of Dario DeLeon and Tommy Valdez

The Graphenstone coating consists of a limestone base which goes through a process called photocatalysis, during which carbon dioxide from the atmosphere is absorbed into the surface, and is then sealed in with graphene, a thin layer of carbon atoms. The murals absorb carbon dioxide throughout the coat’s drying process which typically takes 30 days.

“Each of our murals absorbs about 1600 grams of CO2 during that curing process which is the equivalent daily absorption of about 33 growing trees,” Rose explains.

UXD’s largest carbon-absorbing mural to date is a floor-to-ceiling panorama in downtown Houston’s historic Mellie Esperson building, home to the company’s new creative hub. Painted by Houston-born artist Emily Ding, the mural is a tribute to the establishment’s namesake: an innovative, early 20th century entrepreneur who constructed the opulent building.

"Future's Past" by Emily Ding in partnership with UXD tells the story of the Mellie Esperson building. Photo courtesy of Dario DeLeon

Rose says UXD plans to expand their carbon-absorbing murals project in collaboration with more local artists and establishments, while creating an artist-in-residency program themed around sustainability. Though Rose acknowledges in the grand scheme of carbon pollution these murals are not a silver bullet, he says the non-toxic paints are encouraging conversations about how artists can be conservation-minded.

“We’re trying to figure out how art as a messaging tool can help break down scientific data, a language not many people practice daily, can break down barriers and help bridge the gap to a more intuitive knowledge of sustainability,” Rose says. “We’re bringing the community together, helping them feel empowered, and giving them actionable information to help them live more sustainable lives.”

United Airlines is interested in buying Cemvita's sustainable aviation fuel when it's produced. Photo courtesy of Cemvita

Houston startup with sustainable biotech solutions lands new customer in United Airlines

ready for takeoff

An innovative Houston company is celebrating a new deal with a global airline.

Cemvita Corp. announced a new offtake arrangement with United Airlines. Cemvita's first full-scale sustainable aviation fuel plant will provide up to 1 billion gallons of SAF to United Airlines. The 20-year contract specifies that Cemvita will supply up to 50 million gallons annually to United.

It's not the first collaboration Cemvita has had with the airline. Last year, United invested in the biotech company, which used the funding to open its Houston pilot plant.

“Since our initial investment last year, Cemvita has made outstanding progress, including opening their new pilot plant – an important step towards producing sustainable aviation fuel,” United Airlines Ventures President Michael Leskinen says in a news release. “United is the global aviation leader in SAF production investment, but we face a real shortage of available fuel and producers. Cemvita’s technology represents a path forward for a potentially significant supply of SAF and it’s our hope that this offtake agreement for up to one billion gallons is just the beginning of our collaboration.”

Founded in Houston in 2017 by brother-sister team Moji and Tara Karimi, Cemvita's biotechnology can mimic the photosynthesis process, turning carbon dioxide into feedstock. The company's SAF plan hopes to increase reliability of existing SAFs and lower impact of fuel creation.

“Biology is capable of truly amazing things,” Moji Karimi, CEO of Cemvita, says in the release. “Our team of passionate, pioneering, and persistent scientists and engineers are on a mission to create sustainable BioSolutions that redefine possibilities.”

“We are thrilled to partner with United Airlines in working towards transforming the aviation industry and accelerating the energy transition,” he continues. “This agreement featuring our unique SAF platform is a major milestone towards demonstrating our journey to full commercialization.”

Earlier this year, United, which was reportedly the first airline to announce its goal of net zero carbon emissions by 2050, launched its UAV Sustainable Flight FundSM. The fund, which named Cemvita to its inaugural group of portfolio companies, has raised over $200 million, as of this summer.

Moji and Tara Karimi co-founded Cemvita in 2017. Photo courtesy of Cemvita

------

This article originally ran on EnergyCapital.

Cemvita Factory has made a deal with Houston-based Oxy subsidiary. Courtesy of Cemvita Factory

Oxy backs Houston startup's carbon dioxide-transforming technology

Cha-ching

A Houston startup's carbon dioxide conversion technology has impressed Occidental Petroleum's low carbon subsidiary.

Oxy Low Carbon Ventures LLC has invested an undisclosed amount of funds into Cemvita Factory, the companies announced on August 15.

"One of OLCV's strategic priorities is to develop and commercialize CO2 utilization technologies that complement Occidental's core businesses and product lines, with the goal of helping Occidental find value in new markets and attain its aspiration of becoming carbon neutral," says Richard Jackson, OLCV president, in a news release. "Cemvita Factory's CO2 utilization platform has the potential to harness the power of nature and create new, sustainable pathways for the bio-manufacturing of our products."

Cemvita was founded by two siblings — Moji Karimi, who has a background in the oil and gas industry, and his sister, Tara, who has a background in biotech. Cemvita's biotechnology can replicate photosynthesis — absorbing CO2 and transforming it into glucose or other substances.

While the amount invested in Cemvita isn't disclosed, Moji previously told InnovationMap that he could run a custom pilot program for an energy company for less than $100,000.

"With the investment received from Oxy Low Carbon Ventures, we plan to demonstrate that our technology can economically scale from test tube to the field," Moji, who is the company's CEO, says in the release.

According to the release, Cemvita has a network of clients it is working with to reduce the industry's carbon footprint.

"We have an ambitious goal to take one gigaton of CO2 out of the carbon cycle in the next decade and are very excited about being a part of Occidental's journey to become a carbon-neutral company," says Tara, co-founder and chief scientist, in the release.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.

View All Listings